Amrubicin (CAS 110267-81-7)
See product citations (3)
QUICK LINKS
Amrubicin is primarily utilized in research focused on the study of DNA replication and cell cycle dynamics. As a synthetic anthracycline, it is of particular interest in the field of molecular biology where its influence on topoisomerase II, an enzyme critical for DNA unwinding and replication, is explored. Researchers leverage amrubicin to induce DNA damage in various cancer cell models, which facilitates the study of DNA repair mechanisms and cell death pathways. In addition, amrubicin is used in biochemical assays to understand the role of topoisomerase II inhibitors in transcriptional regulation. Its impact on gene expression is another area of research, as amrubicin can modulate the transcription of certain genes involved in cell proliferation and survival, thereby providing insights into the complex regulation of these processes.
Amrubicin (CAS 110267-81-7) References
- Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride. | Tani, N., et al. 2005. Xenobiotica. 35: 1121-33. PMID: 16418065
- Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. | Yana, T., et al. 2007. Invest New Drugs. 25: 253-8. PMID: 17039404
- Amrubicin for the treatment of small cell lung cancer: does effectiveness cross the Pacific? | Ettinger, DS. 2007. J Thorac Oncol. 2: 160-5. PMID: 17410034
- Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer. | Igawa, S., et al. 2007. J Thorac Oncol. 2: 741-4. PMID: 17762341
- Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. | Inoue, A., et al. 2008. J Clin Oncol. 26: 5401-6. PMID: 18854562
- A phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer. | Fukuda, M., et al. 2009. J Thorac Oncol. 4: 741-5. PMID: 19404211
- Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. | Ettinger, DS., et al. 2010. J Clin Oncol. 28: 2598-603. PMID: 20385980
- Severe interstitial lung disease associated with amrubicin treatment. | Yoh, K., et al. 2010. J Thorac Oncol. 5: 1435-8. PMID: 20683210
- Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin. | Salvatorelli, E., et al. 2012. J Pharmacol Exp Ther. 341: 474-83. PMID: 22338034
- A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901). | Murakami, H., et al. 2014. Lung Cancer. 84: 67-72. PMID: 24530204
- Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509. | Satouchi, M., et al. 2014. J Clin Oncol. 32: 1262-8. PMID: 24638015
- Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients. | Horita, N., et al. 2016. Sci Rep. 6: 18999. PMID: 26750506
- Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. | Yamaoka, T., et al. 1998. Jpn J Cancer Res. 89: 1067-73. PMID: 9849587
- A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. | Hanada, M., et al. 1998. Jpn J Cancer Res. 89: 1229-38. PMID: 9914793
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Amrubicin, 5 mg | sc-207289 | 5 mg | $1051.00 |